Why Pharmaceutical Companies Should Transition to The Cloud

WHAT IS THE CLOUD?

The cloud is an IT platform that allows data, software applications, and various resources for computer processing to be accessed through the Internet on laptops, mobile devices and computers. 

THE BENEFITS OF TRANSITIONING TO THE CLOUD

Pharma companies hold immense amounts of sensitive data, including intellectual property and patient information. Therefore, the need to protect this information is key to a company’s security, as it provides companies the option to store their confidential data and applications on a private cloud, and to utilize the power of the public cloud when necessary. Currently, some type of cloud-based system is being used by almost half of manufactures in the pharma industry, while it is being considered by the rest.   For example, GlaxoSmithKline is currently using Accenture’s cloud platform to speed up the process for their drug development. Also, in June of 2016, Pfizer announced it would being a partnership with Oracle to simplify how it manages its data for clinical trials.

COMMON MYTHS ABOUT TRANSITIONING TO THE CLOUD

MYTH: Cloud protection will be able to thwart and cyber-attack.

CLOUD BEST PRACTICE: Your cloud storage needs to be able to store and hold an adequate amount of data in order to prevent harm from an attack.

MYTH:  Software applications that run in the cloud do not have to be validated.

CLOUD BEST PRACTICE: Software applications that run in the cloud have the same compliance requirements as those that run on premise.

MYTH: Data access is possible around the world if it is within the cloud.

CLOUD BEST PRACTICE: Make sure to use a solution that allows applications and websites to be enhanced for performance on both ends, from the cloud data center to across the Internet to where the other users are located.

Arbour Advantage

Arbour Group can provide the regulatory services necessary to ensure comprehensive cloud compliance that is cost effective and scalable.  We have been a trusted advisor to over 250 life sciences companies and possess the expertise required to address issues in an evolving IT environment.